Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Christopher J. Harrison, Rangaraj Selvarangan, Ferdaus Hassan, Anjana Sasidharan, Wail M. Hassan
Publikováno v:
Open Forum Infectious Diseases
BackgroundEnterovirus (EV) and parechovirus type A3 (PeV-A3) cause infections ranging from asymptomatic to life-threatening. Host immune responses in children, particularly innate responses to PeV-A3, remain largely unknown. The aim of this study was
Autor:
Virginia Amato, Renée Pasciuta, Massimo Clementi, Enrico Papaleo, Nicasio Mancini, Roberto Burioni, Nicola Clementi, Roberto Ferrarese, Paola Viganò, Andrea Salonia, Ana M. Sanchez, Massimo Candiani, Alessandro Ambrosi, L. Quaranta
Publikováno v:
Open Forum Infectious Diseases
Background Vaginal and seminal microbiomes have gained increasing interest for their involvement in reproductive health and fertility. However, their role in reproductive outcome is not fully understood yet. In this study, we aimed to correlate the v
Autor:
Brenda Akoto, Joshua T. Schiffer, Hu Xie, Terry Stevens-Ayers, Elizabeth R. Duke, Danniel Zamora, Bradley C. Edmison, Stephen C. De Rosa, Richard Kiener, Michael Boeckh, Marco Mielcarek, Ralf Wagner
Publikováno v:
Open Forum Infectious Diseases
Background Increased CMV reactivation is observed following discontinuation of letermovir prophylaxis after hematopoietic cellular transplantation (HCT) and decreased CMV-specific polyfunctional T-cell immunity has been proposed as a possible mechani
Autor:
Joshua A. Hill, Michael Boeckh, Damian J. Green, Rebecca Gardner, David G. Maloney, Joyce Maalouf, Carla S Walti, Jim Boonyaratanakornkit, Elizabeth M Krantz, Jacob Keane-Candib, Alexandre V. Hirayama, Merav Bar, Cameron J. Turtle, Justin J. Taylor
Publikováno v:
Open Forum Infectious Diseases
Background Chimeric antigen receptor-modified T (CAR-T) cell immunotherapy for B cell hematologic malignancies results in prolonged B cell depletion. Little is known about the effects of CAR-T cell therapy on pre-existing pathogen-specific humoral im
Publikováno v:
Open Forum Infectious Diseases
Background Endothelin-1 (ET-1) is increasingly recognized as an immune modulator; it exerts a pro-inflammatory effect by increasing the release of cytokines like interferon gamma. ET-1 is secreted by a variety of cells such as macrophages, neurons an
Autor:
Michael Asger Andersen, Joanne Reekie, Marie Helleberg, Carsten Utoft Niemann, Lena Specht, Ashley Roen, Cynthia Terrones-Campos, Amanda Mocroft, Gedske Daugaard, Jens D Lundgren
Publikováno v:
Open Forum Infectious Diseases
Background Cancer treatments suppress immune function and are associated with increased risk of infections, but the overall burden of serious infectious diseases in treated patients has not been clearly elucidated. Methods All patients treated for so
Autor:
Sierra Patterson, Marcos C. Schechter, Maya Fayfman, Guillermo E. Umpierrez, Ravi R. Rajani, David C. Ziemer, Russell R. Kempker, Lubna Smf. Khan
Publikováno v:
Open Forum Infectious Diseases
Background Diabetic foot disease is the leading cause of preventable limb loss in the United States. Care continuum models to measure gaps in care are lacking. Methods Retrospective cohort study conducted in an urban safety-net hospital in Atlanta, G
Publikováno v:
Open Forum Infectious Diseases
Background There is a paucity of literature about the implications of granulomatous disease in hematopoietic stem cell transplant (HSCT) and solid-organ transplant (SOT) patients. Given the broad range of infectious and noninfectious etiologies as we
Publikováno v:
Open Forum Infectious Diseases
Background Although bloodstream infections (BSIs) are important complications of ECMO, data on clinical characteristics of ECMO-associated BSIs remain limited. This study aimed to investigate clinical characteristics of ECMO-associated BSIs and evalu
Autor:
Kathleen A. Dorritie, Robert M. Boudreau, Denise Winfield, Ghady Haidar, Minh Hong Nguyen, Alison R. Sehgal, Palash Samanta, Mounzer Agha, Will Garner
Publikováno v:
Open Forum Infectious Diseases
Background CAR T -cell therapy (CTT) is a novel treatment for B-cell cancers. CTT patients (pt) are at risk of infection due to neutropenia, cytokine release syndrome (CRS), and CAR T-cell related encephalopathy syndrome (CRES), which are treated wit